Start-up company Illumina Inc. is developing a platform that uses fiber optic beaded array technology for genomics, proteomics, pharmaceutical screening, medical diagnostics, and optical olfaction.
You may also be interested in...
Microarray and sequencing specialist Illumina has entered the consumer genomics game with a DTC personal genome sequencing service. It's distancing itself from regulators by partnering with others to handle any secondary data interpretation and dialog with customers, but cautious or not, by reaching out directly to the public, the move does turn on its head the traditional notion of first developing a technology tool for research, then moving on to more regimented clinical applications.
China-specific go-to-market strategies are helping global medtechs access the fast-growing medical device market in China, where localization has become the buzzword for foreign players, writes news and analysis portal Omdia.
While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.